Effects of oral prednisone after stenting in a rabbit model of established atherosclerosis.
暂无分享,去创建一个
R. Virmani | A. Finn | F. Kolodgie | M. Joner | G. Nakazawa | Eduardo Acampado | C. Vassanelli | V. Ferrero | J. Crimins | F. Ribichini | Johanna L Crimins
[1] O. Alfieri,et al. Surgical isolated edge-to-edge mitral valve repair without annuloplasty: clinical proof of the principle for an endovascular approach. , 2006, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[2] Michael Joner,et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.
[3] F. Crea,et al. Immunosuppressive oral prednisone after percutaneous interventions in patients with multi-vessel coronary artery disease. The IMPRESS-2/MVD study. , 2005, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[4] G. Nickenig,et al. Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model , 2005, Zeitschrift für Kardiologie.
[5] M. Hupp,et al. Targeting of αv integrins interferes with FAK activation and smooth muscle cell migration and invasion , 2005 .
[6] G. Stone,et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. , 2005, Journal of the American College of Cardiology.
[7] M. Hupp,et al. Targeting of alpha(v) integrins interferes with FAK activation and smooth muscle cell migration and invasion. , 2005, Biochemical and biophysical research communications.
[8] Gregg W Stone,et al. One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.
[9] C. Rogers,et al. The porcine coronary model of in‐stent restenosis: Current status in the era of drug‐eluting stents , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[10] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[11] R. Virmani,et al. Drug eluting stents: are human and animal studies comparable? , 2003, Heart.
[12] F. Crea,et al. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). , 2002, Journal of the American College of Cardiology.
[13] D. Schlaepfer,et al. FRNK blocks v‐Src‐stimulated invasion and experimental metastases without effects on cell motility or growth , 2002, The EMBO journal.
[14] R. Virmani,et al. Oral Everolimus Inhibits In-Stent Neointimal Growth , 2002, Circulation.
[15] R. Virmani,et al. Pathological Analysis of Local Delivery of Paclitaxel Via a Polymer-Coated Stent , 2001, Circulation.
[16] R. Virmani,et al. Neointimal responses 3 months after 32P β-emitting stent placement , 2000 .
[17] R. Virmani,et al. Neointimal responses 3 months after (32)P beta-emitting stent placement. , 2000, International journal of radiation oncology, biology, physics.
[18] J. Cidlowski,et al. Molecular control of immune/inflammatory responses: interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. , 1999, Endocrine reviews.
[19] W. Fiers,et al. Glucocorticoid-mediated repression of nuclear factor-kappaB-dependent transcription involves direct interference with transactivation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] R. Levy,et al. Site‐specific dexamethasone delivery for the prevention of neointimal thickening after vascular stent implantation , 1994, Coronary artery disease.
[21] V. Hombach,et al. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. , 1994, International journal of cardiology.
[22] R. Alexander,et al. Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. , 1991, Journal of the American College of Cardiology.